Control of bleeding in patients with haemophilia A with inhibitors: a systematic review (Q35163644)

6 August 2017

1 reference

title

Control of bleeding in patients with haemophilia A with inhibitors: a systematic review (English)

1 reference

6 August 2017

0 references

0 references

1 reference

Lloyd Jones M

1

1 reference

6 August 2017

Wight J

series ordinal

2

1 reference

6 August 2017

Paisley S

series ordinal

3

1 reference

6 August 2017

Knight C

series ordinal

4

1 reference

6 August 2017

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

464-520

1 reference

Surgery in hemophilia A patients with factor VIII inhibitor: 10-year experience

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

A Randomized Study of Factor VIII or Prothrombin Complex Concentrate Infusions in Children with Haemophilia and Antibodies to Factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Human factor VIII for bleeding in patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Seventeen years' experience with Autoplex/Autoplex T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00782.X

10.1046/J.1365-2516.2003.00782.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference